Literature DB >> 18354231

Complement receptors 1 and 2 influence the immune environment in a B cell receptor-independent manner.

Amanda C Jacobson1, Janis J Weis, John H Weis.   

Abstract

The CD21/35 proteins are complement receptors implicated in controlling and interpreting activation states of the innate and acquired immune responses. One defect of CD21/35(-/-) animals is depressed production of Ag-specific IgG3 which we show is evident in vivo but not in vitro. Gene expression profiles obtained from naive wild-type and CD21/35(-/-) splenocytes demonstrated enhanced expression of inflammatory mediators from CD11b(+) splenocytes in the CD21/35(-/-) animals. Splenocyte populations between wild-type and CD21/35(-/-) mice were similar except for a moderate increase in GR1(low)CD31(+) immature myeloid cells. Furthermore, depletion of neutrophils and other GR1-expressing cells alleviates elevated inflammatory gene expression in the CD21/35(-/-) spleen. Complement activation also plays a key role in the differential gene expression observed in the CD21/35-deficient mouse as depletion of C3 or inhibition of C3a receptor signaling within the animal returned inflammatory gene expression within the spleen to wild-type levels. Finally, C3 depletion before immunization allowed for the enhanced production of Ag-specific IgG3 production in the CD21/35(-/-) mouse compared with mock-depleted animals. These data suggest that the overall environment of the CD21/35(-/-) spleen is quite different from that of the wild-type animal perhaps due to altered complement convertase activity. This difference may be responsible for a number of the phenotypes ascribed to the deficiency of CD21/35 proteins on B cells and follicular dendritic cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18354231     DOI: 10.4049/jimmunol.180.7.5057

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Generation of a novel Cr2 gene allele by homologous recombination that abrogates production of Cr2 but is sufficient for expression of Cr1.

Authors:  Luke R Donius; Christopher M Orlando; Janis J Weis; John H Weis
Journal:  Immunobiology       Date:  2013-08-21       Impact factor: 3.144

2.  Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice.

Authors:  Alexandra Francian; Shelby Namen; Madigan Stanley; Kristine Mann; Holly Martinson; Max Kullberg
Journal:  Nanomedicine       Date:  2018-11-09       Impact factor: 5.307

3.  A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.

Authors:  Liudmila Kulik; Finnegan B Hewitt; Van C Willis; Rosa Rodriguez; Stephen Tomlinson; V Michael Holers
Journal:  Mol Immunol       Date:  2015-02       Impact factor: 4.407

4.  Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression.

Authors:  Isabel Y Pappworth; Christine Hayes; Jason Dimmick; B Paul Morgan; V Michael Holers; Kevin J Marchbank
Journal:  Immunobiology       Date:  2011-06-25       Impact factor: 3.144

5.  CD21 signaling via C3 regulates Purkinje cell protein 4 expression.

Authors:  Amanda C Jacobson; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-02-07       Impact factor: 4.407

6.  CD21/35 promotes protective immunity to Streptococcus pneumoniae through a complement-independent but CD19-dependent pathway that regulates PD-1 expression.

Authors:  Karen M Haas; Jonathan C Poe; Thomas F Tedder
Journal:  J Immunol       Date:  2009-08-26       Impact factor: 5.422

7.  Optimal germinal center B cell activation and T-dependent antibody responses require expression of the mouse complement receptor Cr1.

Authors:  Luke R Donius; Jennifer M Handy; Janis J Weis; John H Weis
Journal:  J Immunol       Date:  2013-06-03       Impact factor: 5.422

Review 8.  Comparative functional evolution of human and mouse CR1 and CR2.

Authors:  Amanda C Jacobson; John H Weis
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

9.  An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy.

Authors:  Eva-Maria Nichols; Thomas D Barbour; Isabel Y Pappworth; Edwin K S Wong; Jeremy M Palmer; Neil S Sheerin; Matthew C Pickering; Kevin J Marchbank
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

Review 10.  The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases.

Authors:  Vanessa Abella; Morena Scotece; Javier Conde; Rodolfo Gómez; Ana Lois; Jesús Pino; Juan J Gómez-Reino; Francisca Lago; Ali Mobasheri; Oreste Gualillo
Journal:  Biomarkers       Date:  2015-12-15       Impact factor: 2.658

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.